Valisure says the FDA should recall Sanofi’s Zantac and all other ranitidine products “to protect the American public from further exposure to the potentially carcinogenic properties of ...

The FDA has changed its tune about the levels of a suspected carcinogen in Zantac and generic ranitidine drugs.

The move marks the first time the FDA has suggested drug makers should recall the ranitidine heartburn pills since opening a probe several weeks ago.

Shares of Sanofi [: sny] fell 1.78% in trading on Wednesday after the Food and Drug Administration (FDA) issued a voluntary recall of Sanofi's Zantac, a prescription and over-the-counter heartburn ...

"CVS Pharmacy has suspended the sale of all Zantac brand and CVS Health brand ranitidine products until further notice," a spokesperson for the brand wrote in a press release.

CVS and Walgreens suspended sales of Zantac after the FDA said it found small amounts of a probable carcinogen. Here's what we know.

Sanofi said it will voluntarily recall Zantac as the drugmaker and FDA investigate the source of NDMA, a probable carcinogen.

Lab tests detected increased levels of a contaminant in the products caused when not properly stored A formal recall has been issued to clear Zantac products from store shelves across the country ...

(RTTNews) - The U.S. Food and Drug Administration has urged to withdraw Sanofi's heartburn drug Ranitidine as well as its generics from the market with immediate effect for possible contamination ...

An ongoing FDA investigation has determined that levels of a contaminant in the heartburn medication can pose a risk to public health.

Testing of ranitidine for injection is still ongoing.” The FDA is also asking drug makers to recall nizatidine, also known as Axid, if it tests as having NDMA above the levels set for ranititidne.